Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Effect on metabolic and hormonal patterns.
OBJECTIVE
The primary objective of this investigation was to evaluate the anticatabolic effects of repeated subcutaneous administration of recombinant human insulin-like growth factor-I (rhlGF-I) in patients after gastric surgery.


BACKGROUND
The anabolic and protein-sparing effects of growth hormone are primarily mediated by IGF-I. Malnutrition and catabolic states result in increasing blood levels of growth hormone and decreasing levels of IGF-I. Experimental data showed that exogenous IGF-I could attenuate or reverse catabolism.


METHODS
After giving their written informed consent, 38 male and female patients undergoing gastrectomy (age 40-75 years, body mass index 17-30 kg/m2) were treated with 80 micrograms/kg body weight rhlGF-I or placebo in a prospective, randomized, double-blind study for 5 consecutive days. Patients received a standardized total parenteral nutritional regimen with 3 g/kg body weight glucose and 0.1 g/kg body weight nitrogen. Nitrogen balance and 3-methylhistidine excretion were measured daily. Hormone profiles (IGF-I, IGFBP1, IGFBP3, cortisol, insulin, glucagon, triiodothyronine [T3], levothyroxine [T4], and thyroxine-binding globulin) were taken.
D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D004311:Double-Blind Method; D005260:Female; D005743:Gastrectomy; D006728:Hormones / Q000097:blood; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000008:administration & dosage* / Q000032:analysis; D008297:Male; D008660:Metabolism / Q000187:drug effects; D008875:Middle Aged; D011182:Postoperative Care; D011446:Prospective Studies; D011994:Recombinant Proteins / Q000008:administration & dosage
D001786:Blood Glucose; D006728:Hormones; D011994:Recombinant Proteins; D007334:Insulin-Like Growth Factor I